礼来公司的减肥药替西帕肽在中国获得批准

Reuters07-19

((自动化翻译由路透提供，请见免责声明 )) Andrew Silver

路透上海7月19日 - 礼来周五在社交媒体 (link)，称其减肥药替扎帕肽已获得中国监管机构的批准，进一步加剧了与丹麦竞争对手诺和诺德在这一重要亚洲市场的竞争。

诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 (link)。

礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗（Mounjaro）和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 (link)。

据估计，到本十年末，全球减肥市场的规模将达到至少1000亿美元，礼来和诺和诺德公司正在竞相提高产量。这两家公司的肥胖症治疗药物都属于最初为糖尿病开发的一类药物，被称为 GLP-1 激动剂。

研究表明，GLP-1 药物可帮助患者平均减轻 20% 的体重，从而刺激了无与伦比的需求。

(1 美元 = 6.8673 丹麦克朗)

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452441340?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-19 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452441340","market":"sh","top_or_hot":-1,"title":"礼来公司的减肥药替西帕肽在中国获得批准","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 )) Andrew Silver</p><p>    路透上海7月19日 - <a href=\"https://laohu8.com/S/LLY\">礼来</a>  周五在社交媒体 (link)，称其减肥药替扎帕肽已获得中国监管机构的批准，进一步加剧了与丹麦竞争对手<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>  在这一重要亚洲市场的竞争。</p><p>诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 (link)。 </p><p>礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗（Mounjaro）和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 (link)。</p><p>据估计，到本十年末，全球减肥市场的规模将达到至少1000亿美元，礼来和诺和诺德公司正在竞相提高产量。这两家公司的肥胖症治疗药物都属于最初为糖尿病开发的一类药物，被称为 GLP-1 激动剂。</p><p>研究表明，GLP-1 药物可帮助患者平均减轻 20% 的体重，从而刺激了无与伦比的需求。</p><p>(1 美元 = 6.8673 丹麦克朗) </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来公司的减肥药替西帕肽在中国获得批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来公司的减肥药替西帕肽在中国获得批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-19 16:40 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 )) Andrew Silver    路透上海7月19日 - 礼来  周五在社交媒体 (link)，称其减肥药替扎帕肽已获得中国监管机构的批准，进一步加剧了与丹麦竞争对手诺和诺德  在这一重要亚洲市场的竞争。诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 (link)。 礼来...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2452441340","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452441340","pubTimestamp":1721378400,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 。礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4588":"碎股","BK4007":"制药","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","NVO":"诺和诺德","LU0122379950.USD":"贝莱德世界健康科学A2","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LLY":"礼来","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4581":"高盛持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0079474960.USD":"联博美国增长基金A","LU0882574139.USD":"富达环球消费行业基金A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"Eli Lilly's weight-loss pill tisiparatide gets approved in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":0.9,"LLY":0.8},"content_text":"((自动化翻译由路透提供，请见免责声明 )) Andrew Silver    路透上海7月19日 - 礼来  周五在社交媒体 (link)，称其减肥药替扎帕肽已获得中国监管机构的批准，进一步加剧了与丹麦竞争对手诺和诺德  在这一重要亚洲市场的竞争。诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 (link)。 礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗（Mounjaro）和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 (link)。据估计，到本十年末，全球减肥市场的规模将达到至少1000亿美元，礼来和诺和诺德公司正在竞相提高产量。这两家公司的肥胖症治疗药物都属于最初为糖尿病开发的一类药物，被称为 GLP-1 激动剂。研究表明，GLP-1 药物可帮助患者平均减轻 20% 的体重，从而刺激了无与伦比的需求。(1 美元 = 6.8673 丹麦克朗)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452441340"}